| SIEMENS HEALTHCARE DIAGNOSTICS INC. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120135916 | MONOMERIC AND DIMERIC FORMS OF ADIPONECTIN RECEPTOR FRAGMENTS AND METHODS OF USE - Methods are disclosed for determining progression of a condition, onset of a condition, or efficacy of treatment of a condition characterized by an adipocyte imbalance in a patient. In addition, methods are disclosed of treating diabetes, abnormal adipocyte activity, and insulin resistance using monomeric, homodimeric, and heterodimeric forms of certain C-terminal fragments of adiponectin receptor. In addition, methods of treating abnormal adipocyte activity, treating metabolic syndrome, causing insulin secretion, increasing insulin levels, inhibiting insulin degradation enzyme, treating Alzheimer's disease, treating cardiovascular disease associated with adiponectin levels, inhibiting ADAM-17 enzyme, inhibiting a protease, treating a condition associated with TNF-alpha, and treating a condition associated with HER2-neu are disclosed. Compositions, dosage forms, and kits are also disclosed. | 05-31-2012 |
| 20120134769 | Methods, Systems, And Apparatus Adapted To Transfer Sample Containers - A method adapted to transfer a sample container such as a capped sample tube is disclosed. In one aspect, the method includes gripping a sample tube body with a first gripper pair and a cap with a second gripper pair of a gripper apparatus. In another aspect, a seating member may contact the cap to aid in the positioning of the sample container. Apparatus and systems for carrying out the method are provided, as are other aspects. | 05-31-2012 |
| 20120127821 | Method For Mixing Liquid Samples In A Container Using A Lemniscate Stirring Pattern - A method for rapidly and uniformly mixing solutions within a biochemical analyzer by rapidly and repeatedly moving a sampling probe in generally lemniscate shaped pattern within the solution is provided. | 05-24-2012 |
| 20120115174 | URINARY TRYPSIN INHIBITORS AS DIAGNOSTIC AID FOR INTERSTITIAL CYSTITIS - A method aiding the diagnosis of interstitial cystitis involving the combination of an infection marker and an inflammation marker. More specifically, the method includes correlating the presence of urinary trypsin inhibitors in urine with the absence of traditional infection markers in urine to aid in the diagnosis of interstitial cystitis. The method provides for a differential diagnosis between kidney disease, infection and chronic inflammation with a noninvasive urine test. Assay devices and kits, as well as analyzers and systems are also described that utilize the methodology. | 05-10-2012 |
| 20120072027 | METHOD AND APPARATUS FOR LOW-VOLUME ANALYZER WITH FIXED AND VARIABLE INDEXING - A sample analyzer with fixed and variable indexing that is structured and arranged to align reaction vessels, e.g., cuvettes, at a pre-determined, fixed point while maintaining a positional sequence using variable indexing. Variable indexing allows cuvettes to be presented to multiple, fixed point resources at multiple occasions in a systematic progression in a highly efficient manner. The presentation of cuvettes to multiple, fixed point resources at multiple times is superior to existing indexing. | 03-22-2012 |
| 20120064546 | METHODS FOR DETECTION OF HYDROPHOBIC DRUGS - Methods and reagents are disclosed for pretreating a sample suspected of containing a hydrophobic drug for conducting an assay method for detecting the hydrophobic drug. A combination is provided in a medium that includes the sample, a releasing agent for releasing the hydrophobic drug and the metabolites from endogenous binding moieties, and a selective solubility agent that provides for substantially equal solubility of the hydrophobic drug and the metabolites in the medium. The selective solubility agent includes a water miscible, non-volatile organic solvent and is present in the medium in a concentration sufficient to provide for substantially equal solubility of the hydrophobic drug and the metabolites in the medium. The medium, which may further include a hemolytic agent, is incubated under conditions for releasing the hydrophobic drug and the metabolites from endogenous binding moieties. The pretreated sample may be subjected to an assay for determining the hydrophobic drug. | 03-15-2012 |
| 20120045847 | ASSAY FOR ANALYTES USING MULTIPLE RECEPTORS - A method for determining an analyte in a sample suspected of containing the analyte comprises providing in combination a medium, the sample, and two or more different receptors. Each different receptor binds to at least two different epitopic sites. One of the epitopic sites is a common binding site and one of the epitopic sites is non-common binding site. The non-common epitopic sites are different for each different receptor. The receptors exhibit mono-molecular binding. The medium is incubated under conditions for binding of the receptors to the epitopic sites. The medium is examined for the presence and/or amount of complexes comprising the epitopic sites and the receptors. The presence and/or amount of the complexes indicate the presence and/or amount of the analyte in the sample. | 02-23-2012 |
| 20120034629 | PREDICTION OF NON-FATAL AND FATAL ATHEROTHROMBOTIC EVENTS - The present invention relates to methods and systems for the prediction of atherothrombotic events in human subjects. Preferably the human subjects are afflicted with a cardiovascular disease, such as end-stage renal disease. Methods and systems of the invention are particularly suited to predict atherothrombotic events in patients on hemodialysis. | 02-09-2012 |
| 20110318754 | Reduction in False Results in Assay Measurements - Methods and reagents are disclosed for detecting a false result in an assay measurement for determining a concentration of an analyte in a sample suspected of containing the analyte. The method comprises measuring assay signal resulting from background only and measuring assay signal resulting from the presence of analyte in the sample plus background and subtracting the first measurement from the second measurement to determine the concentration of analyte in the sample. For example, a measurement result 1 is determined by means of an assay conducted on a portion of the sample where analyte in the sample is substantially sequestered and a measurement result 2 is determined by means of the assay conducted on an equal portion of the same sample where analyte in the sample is substantially non-sequestered. Measurement result 1 is subtracted from measurement result 2 to determine the concentration of analyte in the sample. | 12-29-2011 |
| 20110306148 | COMPOSITION FOR USE AS AN ASSAY REAGENT - A composition for use as an assay reagent comprises a solid support comprising a member of a signal producing system and a coating of a synthetic copolymer. The synthetic copolymer comprises a first polymerized monomer comprising a pendant moiety comprising a reactive functionality or a derivative of a reactive functionality and a second polymerized monomer comprising a pendant moiety comprising at least 1 carbon atoms and at least 2 heteroatoms. In some embodiments the copolymer comprises a polyethylenic backbone comprising the pendant moiety comprising a reactive functionality or a derivative of a reactive functionality and the pendant moiety comprising at least 1 carbon atom and at least 2 heteroatoms. | 12-15-2011 |
| 20110301089 | ADIPONECTIN RECEPTOR FRAGMENTS AND METHODS OF USE - Methods are disclosed of treating diabetes, abnormal adipocyte activity, and insulin resistance using C-terminal fragments of adiponectin receptor R1. Methods of causing the secretion of insulin in healthy and diabetic patients using C-terminal fragments of adiponectin receptor R1 are also disclosed. In addition, methods are disclosed of increasing the insulin levels in healthy patients using C-terminal fragments of adiponectin receptor R1. In addition, methods of treating abnormal adipocyte activity, treating metabolic syndrome, causing insulin secretion, increasing insulin levels, inhibiting insulin degradation enzyme, treating Alzheimer's disease, treating cardiovascular disease associated with adiponectin levels, inhibiting ADAM-17 enzyme, treating a condition associated with TNF-alpha, and treating a condition associated with HER2-neu are disclosed. Compositions, dosage forms, and kits are also disclosed. | 12-08-2011 |
| 20110294221 | CONTROL BRACKETING AND RESULTS HOLD - An automated immunoassay analyzer, or assay system, provides for frequent testing of control samples to verify that before and after a series of tests of patients' samples, the operation of the test equipment is accurate, thereby ensuring that the results of the series of patient tests are accurate. Operating the immunoassay analyzer in this manner will delay reporting clinical test results until the results are confirmed as accurate. This operation can be performed automatically by a random access immunoassay analyzer. | 12-01-2011 |
| 20110281279 | CIRCULATING Epha2 RECEPTOR - Provided are compositions, methods, and kits relating to the detection of a circulating or soluble form of the EphA2 receptor tyrosine kinase. | 11-17-2011 |
| 20110275104 | Device and Method for Detection of Humidity-Compromised Urine Test Strips - The timing of the reaction of moisture-sensitive reagents for detecting the presence of analytes, e.g. leukocytes in urine samples, is used to detect when the reagents have been compromised by excess humidity. The ratio of light reflectance at wavelengths characteristic of the products of reaction between the reagents and the analyte and an infra-red reference dye is measured at two preset times after a urine sample has been applied to a test strip and used to determine whether the reagents have been compromised by excessive humidity. The presence of unusually dark samples is determined from the reflected light at 470 and 625 nm in order to confirm that the test strips are humidity-compromised. | 11-10-2011 |
| 20110275095 | Microarrays for Allergen-Specific IgE - Biological samples are assayed for the presence of IgE antibodies specific to unknown allergens in the samples. Known allergens conjugated to biotin are attached as an array of spots on a streptavidin-linked membrane. A sample is incubated with the membrane containing attached known allergens. After washing away excess sample, the membrane is contacted with a labeled anti-IgE, e.g. alkaline phosphatase-labeled anti-IgE, thus attaching anti-IgE to the IgE from the sample, now bound to known allergens. The excess labeled anti-IgE is washed away and the attached IgE remaining on the membrane identified by adding a substrate for the label, thus producing a measurable response. | 11-10-2011 |
| 20110268329 | METHOD AND APPARATUS FOR DETERMINING A LIQUID LEVEL IN A CONTAINER USING IMAGING - Methods, systems and apparatus for determining a level of a sample are provided. An image of a sample housed in a container is captured, wherein the image is represented as a two dimensional array of intensities of light. An area of interest is extracted from the image. A filter is applied to the area of interest. The filtered area is collapsed into a one dimensional array. The one dimensional array is masked. The level of the sample in the container is determined based on the masked one dimensional array. Numerous other aspects are provided. | 11-03-2011 |
| 20110267450 | METHODS AND APPARATUS FOR AUTOMATED DETECTION OF THE PRESENCE AND TYPE OF CAPS ON VIALS AND CONTAINERS - Methods, systems and apparatus for determining the presence of a cap on a container are provided. An exemplary method comprises capturing an image of an object; extracting an area of interest from the image; determining from the image a position of one or more edges of the object; and determining the presence of a cap based on a comparison of the one or more edge positions to reference data. Numerous other aspects are provided. | 11-03-2011 |
| 20110262304 | METHOD OF FLUID CONTROL IN MEDICAL DIAGNOSTIC MEDIA - Migration of liquid samples on diagnostic test strips is prevented by dividing the test strips into reagent-containing pads spaced about 0.3 to 3 mm apart with a laser. | 10-27-2011 |
| 20110245483 | Method For Purification Of Nucleic Acids, Particularly From Fixed Tissue - The invention relates to a method for purification of nucleic acids, to a kit for performing the method according to the invention and to a new application of magnetic particles for purification of a biological sample. The method according to the invention comprises the following steps: a) accommodating of the sample in a first sample vessel in an aqueous solution and lysing of the sample under non-chaotropic conditions; suspending of first magnetic particles in the solution and inserting of the first sample vessel in a sample vessel holder, wherein the sample vessel is inserted in the annular interior space of a ring magnet associated with the sample vessel holder; separating of the solution from the magnetic particles; and isolating of the nucleic acids from the solution. | 10-06-2011 |
| 20110236997 | Methods and Reagents for Shortening Incubation Times in Hybridization Assays - The methods and reagents described herein can be used to shorten incubation times in hybridization assays. As demonstrated in the examples, we have identified specific sulfonic acid polymers and hybridization conditions that lead to significantly shorter incubation times (e.g., signals after three hours that are comparable to signals that could traditionally only be obtained after overnight incubation). In some embodiments, shorter incubation times are achieved by adding the sulfonic acid polymer(s) during the hybridization process. Alternatively or additionally, in some embodiments, shorter incubation times are achieved via changes to the hybridizing conditions, e.g., by reducing the hybridization volume, increasing the salt concentration, and/or increasing the probe concentration (capture extender probe and/or label extender probe). | 09-29-2011 |
| 20110230638 | METHODS FOR DETECTION OF CYCLOSPORIN A - Methods and reagents are disclosed for determining the presence and/or amount of cyclosporin A in a medium suspected of containing cyclosporin A. In the method a combination is provided in a medium. The combination comprises (i) the sample, (ii) a first member of a signal producing system (sps) associated with a first support wherein the first sps member is capable of activating a second member of the sps and wherein the first support is associated with a first member of a specific binding pair, and (iii) the second sps member associated with a second support wherein the second sps member is activatable by the first sps member. The second support comprises either (I) cyclosporin C or cyclosporin A and the combination further comprises a conjugate of an antibody for cyclosporin A and a second member of the specific binding pair or (II) antibody for cyclosporin A and the combination further comprises a conjugate of cyclosporin A and a second member of the specific binding pair. The combination is subjected to conditions for binding of cyclosporin A to the antibody for cyclosporin A. The first sps member is activated and the amount of signal generated by the second sps member is detected. The amount of signal is related to the presence and/or amount of cyclosporin A in the sample. | 09-22-2011 |
| 20110223673 | Polarized Optics for Optical Diagnostic Device - A readhead for a photometric diagnostic instrument includes a holder configured for receiving reagent sample media therein. The sample media has a plurality of test areas configured to react with, and change color, according to an amount of an analyte in a sample. The holder is sized and shaped for forming an indexed fit with the sample media. One or more light sources are configured to emit light onto the test areas. First and second polarized light filters are respectively disposed between the light sources and the test areas, and between the test areas and one or more light detectors, so that the light detectors receive diffuse, non-specular reflections of the light from the test areas, while substantially preventing the light detectors from receiving specular reflections of the light. | 09-15-2011 |
| 20110180426 | Modulating Polarization Voltage of Amperometric Sensors - The service life of amperometric electrochemical oxygen sensors is increased by operating the electrodes of such sensors at a polarization voltage suitable for measuring the oxygen content of samples only during calibration or when measuring such samples and thereafter modulating the polarization voltage to a lower voltage such that substantially no electrical current is produced by the electrodes. | 07-28-2011 |
| 20110149277 | Multi-Layer Slides for Analysis of Urine Sediments - Visual analysis of urine samples is carried out with the use of a slide consisting of three layers containing an enclosed viewing chamber which receives a urine sample deposited by pipette into an opening on the outer layer of the slide. From the inlet opening the sample enters an inlet chamber in the middle layer and passes through a capillary passageway into the viewing chamber where it is inspected for particles and sediments. | 06-23-2011 |
| 20110143946 | Method for predicting the response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent - The present invention relates to a method for predicting a response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent, said method comprising the steps of: a) obtaining a biological sample from said patient; b) determining the pattern of expression level of at least one gene of the group comprising AKR1C1, MLPH, ESR1, PGR, COMP, DCN, IGKC, CCL5, FBN1 and/or UBE2C, or of genes coregulated therewith, in said sample; c) comparing the pattern of expression levels determined in (b) with one or several reference pattern (s) of expression levels; d) identifying at least one marker gene; e) determining a molecular subtype for said sample on the basis of (d); and f) predicting from said molecular subtype response of a tumor for a chemotherapeutic agent, wherein the molecular subtype is selected from the group comprising the subtypes basal, stromal-high, stromal-low, luminal A, immune system-high, immune system-low, proliferation-high and/or proliferation-low. | 06-16-2011 |
| 20110139638 | Use of Polyoxyalkylene Nonionic Surfactants with Magnesium Ion Selective Electrodes - Methods are disclosed for reducing the shift in EMF bias in a magnesium ion selective electrode, comprising the step of: contacting the electrode with a composition comprising a polyoxyalkylene nonionic surfactant; wherein the polyoxyalkylene nonionic surfactant has an HLB greater than about 18. Additional aspects of the present invention are directed to methods, comprising the steps of: contacting a magnesium ion selective electrode with a composition comprising a polyoxyalkylene nonionic surfactant, wherein the polyoxyalkylene nonionic surfactant has an HLB greater than about 18; and measuring a biologically relevant level of a blood electrolyte in a blood composition with the electrode. In certain embodiments, the polyoxyalkylene nonionic surfactant is polyoxy ethylene (100) stearyl ether and the blood electrolyte is magnesium ion. | 06-16-2011 |
| 20110136136 | Methods For Detection Of Hydrophobic Drugs - Methods and reagents are disclosed for pretreating a sample suspected of containing a hydrophobic drug for conducting an assay method for detecting the hydrophobic drug. A combination is provided in a medium. The combination comprises (i) the sample, (ii) a releasing agent for releasing the hydrophobic drug and the metabolites from endogenous binding moieties, and (iii) a selective solubility agent that provides for substantially equal solubility of the hydrophobic drug and the metabolites in the medium. The selective solubility agent comprises a water miscible, non-volatile organic solvent and is present in the medium in a concentration sufficient to provide for substantially equal solubility of the hydrophobic drug and the metabolites in the medium. The medium, which may further comprise a hemolytic agent, is incubated under conditions for releasing the hydrophobic drug and the metabolites from endogenous binding moieties. For conducting an assay for the hydrophobic drug, the above pretreatment is performed and to the medium is added reagents for determining the presence and/or amount of the hydrophobic drug in the sample wherein the reagents comprise at least one antibody for the hydrophobic drug. The medium is examined for the presence of a complex comprising the hydrophobic drug and the antibody for the hydrophobic drug, the presence and/or amount of the complex indicating the presence and/or amount of the hydrophobic drug in the sample. | 06-09-2011 |
| 20110136107 | Diagnostics and Therapeutics for Diseases Associated with G-Protein Coupled Receptor AdipoR2 (AdipoR2) - The invention provides human AdipoR2 which is associated with the cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, respiratory diseases, inflammation, neurological diseases, urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, respiratory diseases, inflammation, neurological diseases, urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of AdipoR2 as well as pharmaceutical compositions comprising such compounds. | 06-09-2011 |
| 20110124013 | Galactose-alpha-1,3-galactose-macromolecule conjugates and methods employing same - Methods and reagents are disclosed for conducting assays for IgE. Embodiments of the present reagents comprise a conjugate of a macromolecule and a compound comprising a galactose-α-1,3-galactose epitope. Embodiments of the present methods are directed to determining the presence and/or amount of an IgE specific for a galactose-α-1,3-galactose epitope in a sample. A combination is provided in a medium, which comprises the sample and a reagent for determining the presence and/or amount of an IgE specific for a galactose-α-1,3-galactose epitope in a sample wherein the reagent comprises a conjugate of a macromolecule and a compound comprising a galactose-α-1,3-galactose epitope. The combination is subjected to conditions for binding of the IgE to the reagent to form a complex. The presence and/or amount of the complex are detected and the amount of the complex is related to the presence and/or amount of IgE in the sample. | 05-26-2011 |
| 20110118141 | Disease Specific Diagnostic Aid - A disease specific panel having at least one primary test for different analytes that are relevant for either early detection of a primary disease or management of patients already diagnosed with said primary disease. The panel also includes at least one secondary test which is relevant for detection of a co-morbid condition or complications of the primary disease. Generally, the primary and secondary tests are disposed on a support surface. The disease specific panel is different from the prior art creening tests in that there are no tests included in the panel whose results are not relevant or do not relate to either primary disease or a co-morbid condition or complications of the primary disease. The disease specific panel may also include systems and methods utilizing algorithms for creating and outputting diagnostic aids, as well as warnings about the presence of possible sample interferants, especially those commonly associated with the subject disease of the panel. | 05-19-2011 |
| 20110111522 | NON-VISIBLE DETECTABLE MARKING FOR MEDICAL DIAGNOSTICS - Sample media for the analysis of analytes in a fluid test sample includes a carrier, at least one test field on the surface of the carrier including at least one reagent reactive with the analytes and capable of providing a detectable response. A non-visible bar code formed by at least two distinct non-visible marker fields is located on the carrier. The marker fields are configured to reflect electro-magnetic (EM) radiation within one or more ranges of non-visible wavelengths to form a coded sequence of reflectances correlated to identification of the sample media. | 05-12-2011 |
| 20110092691 | Method For Filtering Nucleic Acids, In Particular From Fixed Tissue - The invention relates to a method for filtering nucleic acids, to a kit for carrying out the method according to the invention and to a novel use of magnetic particles for filtering a biological sample. The method according to the invention comprises the following steps: a) the sample is held in an aqueous solution; b) lysing of the sample; c) separation of cellular debris; and d) the nucleic acids are isolated from the solution, steps (a) to (c) taking place under non-chaotropic conditions. | 04-21-2011 |
| 20110091978 | STABILIZATION OF SIGNAL GENERATION IN PARTICLES USED IN ASSAYS - Methods and reagents are disclosed for conducting assays. Embodiments of the present methods and reagents are concerned with a solid support such as, for example, a particle. The support comprises a chemiluminescent composition that comprises a metal chelate. The present inventors observed that, when such support such as, e.g., particles, were employed in assays for the determination of an analyte, stability of signal output by the chemiluminescent composition associated with the particle was unacceptably reduced as compared to particles comprising other chemiluminescent compositions. In accordance with embodiments of the present invention, the stability of signal output from such particles is enhanced by including in a medium comprising the particles a sufficient amount of one or more stabilizing agents, which may be a chelating agent and/or a metal chelate such as, for example, the metal chelate that is associated with the particle. | 04-21-2011 |
| 20110065108 | Urine Transport Medium - A method of stabilizing a patient sample such as a urine sample to prevent degradation of nucleic acids for subsequent analysis for pathogen detection involves adding a stabilizing solution to an aliquot of the sample. A stabilizing solution comprising a chaotrope, a non-ionic detergent, and a buffer preserves urine samples for at least 28 days at room temperature for storage and transportation to an analytical facility for screening for pathogen nucleic acids. | 03-17-2011 |
| 20110044854 | Method for Increasing Throughput in an Automatic Clinical Analyzer by Duplicating Reagent Resources - A method for maximizing analyzer throughput irregardless of the mix in demand of different assays to be conducted by duplicating the reagents required to conduct selected assays in at least two separate reagent servers and also enabling newly incoming selected assays to be conducted using reagents from whichever reagent server has the smaller backlog of such high-volume assays. | 02-24-2011 |
| 20110039275 | Method for Predicting a Clinical Response of a Patient Suffering from or at Risk of Developing Cancer Towards a Given Mode of Treatment - The present invention relates to a method for predicting a clinical response of a patient suffering from or at risk of developing cancer, preferably colorectal cancer, towards a given mode of treatment, said method comprising the steps of: a) obtaining a biological sample from said patient; b) determining the expression level of at least SPON-2, and optionally determining the expression level of SPON-1, in said sample; c) comparing the expression level or expression levels determined in (b) with one or several reference expression levels; and d) predicting therapeutic success for said given mode of treatment in said patient or implementing therapeutic regimen in said subject from the outcome of the comparison in step (C). | 02-17-2011 |
| 20110020791 | Methods and Materials for Detecting Mutations in Quasispecies Having Length Polymorphisms - The present invention is directed to a method for detecting the presence or absence of a mutation of interest in the nucleic acid of a pathogen, wherein the mutation of interest is located adjacent to a length polymorphism defining multiple quasispecies of the pathogen. | 01-27-2011 |
| 20110013180 | Method and Apparatus for Auxiliary Illumination for Detecting an Object - A detection system and method for detecting an object such as a vessel or a cap on a vessel. The system includes an imaging device having a lens with a field of view for registering and processing an image of the object, an illumination device(s) for actively illuminating the object, a dark background portion, and an auxiliary light reflective area(s) for passively illuminating an edge portion of the object using reflections of illumination from the illumination device(s). The auxiliary light reflective area(s) is/are disposed adjacent to the dark background portion out of the field of view of the lens. Images of the object are subsequently compared to images of reference objects. | 01-20-2011 |
| 20110003309 | Non-Competitive Internal Controls for Use in Nucleic Acid Tests - Provided are non-competitive internal controls for use in nucleic acid tests (NATs), which are obtained from the organisms | 01-06-2011 |
| 20100330548 | Nucleic Acid Primers and Probes for Detecting Human and Avian Influenza Viruses - Provided are nucleic acid sequences that are used to prepare primers and probes that are used in a kinetic polymerase chain reaction (kPCR) assay to detect influenza viruses in a human or animal subject. The starting material for the kPCR assays may be DNA or RNA and the assays may be conducted in a singleplex assay to detect a single influenza virus or in a multiplex assay to detect multiple influenza viruses. The primers and probes have utility in the detection and quantification of type A and type B influenza viruses (INFA and INFB, respectively) and have been shown to be effective for the detection and quantification of all the known INFA subtypes, namely, H1, H2, H3, H4, H5, H6, H7, H8, and H9. | 12-30-2010 |
| 20100310426 | REAGENT CARTRIDGE - A self dispensing reagent cartridge includes a vessel with a movable piston at one end and a puncturable self sealing septum at an opposite end. A hollow needle is located in alignment with the septum. The vessel is moved toward the needle to enable the needle to puncture the septum. The piston is then moved toward the septum to enable a predetermined amount of liquid in the vessel to be transferred outwardly of the vessel through the needle in an amount corresponding to the piston stroke. | 12-09-2010 |
| 20100297670 | METHODS FOR DETECTION OF IMMUNOSUPPRESSANT DRUGS - Methods and reagents are disclosed for enhancing the bioavailability of a hydrophobic drug, and in some embodiments for determining a hydrophobic drug, in a sample suspected of containing a hydrophobic drug. A combination is formed in a medium where the combination comprises the sample, a hemolytic agent where a determination of the hydrophobic drug is conducted, and a bioavailability agent for the hydrophobic drug. The bioavailability agent comprises an ionic detergent comprising a chain of at least 10 carbon atoms or a non-ionic detergent comprising a chain of at least 15 repeating ethylene oxide units or propylene oxide units or a combination of ethylene oxide units and propylene oxide units. The concentration of the bioavailability agent in the medium is sufficient to enhance the bioavailability of the hydrophobic drug. The medium is incubated under conditions for enhancing the bioavailability of the hydrophobic drug, and in a determination of the hydrophobic drug under conditions for hemolyzing cells in the sample. For determination of the hydrophobic drug, reagents for determining the presence and/or amount of the hydrophobic drug in the sample are added to the medium. The reagents comprise at least one antibody for the hydrophobic drug. The medium is examined for the presence of a complex comprising the hydrophobic drug and the antibody for the hydrophobic drug. The presence and/or amount of the complex indicates the presence and/or amount of the hydrophobic drug in the sample. | 11-25-2010 |
| 20100273181 | METHODS FOR THE DETECTION OF GLYCATED HEMOGLOBIN - Particular aspects of the present invention relate to methods for detecting glycated hemoglobin in, for example, human whole blood, that are not affected by the presence of variation in amino acid sequence that can exist in hemoglobin β chains. The methods detect all glycated hemoglobin in a sample, regardless of the form of the hemoglobin that has been glycated, and thus detect glycated human Hemoglobin A, Hemoglobin S, and Hemoglobin C. | 10-28-2010 |
| 20100271479 | METHOD AND APPARATUS FOR REMOTE MULTIPLE PROCESS GRAPHICAL MONITORING - A network of controllers for controlling and monitoring associated assay testing systems coupled to a remote monitoring unit for monitoring and controlling the controllers and/or the assay testing systems is disclosed. Each controller transmits a display image representing the status of the respective assay-testing system. The remote monitoring unit automatically detects if the number of display images from the controllers is greater than a threshold number of displayable, static thumbnail images and, when the threshold is exceeded, displays thumbnail images dynamically in a scrolling or streaming motion. The thumbnail images, whether static or dynamic, are updated in real-time or pseudo-real-time to reflect updated status of the assay testing systems. | 10-28-2010 |
| 20100267058 | CIRCULATING RET RECEPTOR - Provided are compositions, methods, and kits relating to the detection of a circulating or soluble form of the KET receptor tyrosine kinase. | 10-21-2010 |
| 20100261157 | Device and Method for Processing a Sample Contained in a Swab for Diagnostic Analysis - A device for processing a sample contained in a swab for diagnostic analysis, includes a chamber having a first chamber portion and a second chamber portion to receive the swab and a processing fluid, wherein at least one of the first and second chamber portions is flexible. A divider may be positioned in the chamber to facilitate transferring the sample to the second chamber portion, and a delivery channel is disposed in fluid communication with at least one of the first chamber portion and the second chamber portion to deliver a processed sample for diagnostic analysis. | 10-14-2010 |
| 20100255482 | Hepatitis B Virus (HBV) Specific Oligonucleotide Sequences - The present invention relates to oligonucleotide sequences for amplification primers and detection probes and to their use in nucleic acid amplification methods for the detection of HBV in biological samples. In particular, oligonucleotide sequences are provided for the sensitive qualitative or quantitative detection of all eight HBV genotypes. The invention also provides oligonucleotide primer sets and primer/probe sets in the form of kits for the diagnosis of HBV infection. | 10-07-2010 |
| 20100248220 | Chlamydia Trachomatis Specific Oligonucleotide Sequences - The present invention relates to oligonucleotide sequences for amplification primers and detection probes and to their use in nucleic acid amplification methods for the selective and specific detection of | 09-30-2010 |
| 20100239137 | Two Dimensional Imaging of Reacted Areas On a Reagent - A system for reading an assay includes a camera and a processor. The assay is used as a test for the presence or absence of a reaction between a sample and a reagent. The assay is defined by a test area and a background area. The test area is, preferably, substantially circular with a diameter between about 0.1 mm and about 5 mm. The camera simultaneously captures a two-dimensional image of the test area and the background area. The processor determines a first color response from the background area and a second color response from the test area. The processor then calibrates the second color response according to the first color response and generates a result of the test according to the second color response. The system may also include a uniform field illuminator that provides a substantially uniform level of illumination across the assay. | 09-23-2010 |
| 20100233680 | Gene Expression Profiles and Methods of Use - The present invention relates to gene expression profiles, microarrays comprising nucleic acid sequences representing gene expression profiles, and methods of using expression profiles and microarrays. The invention also provides methods and compositions for diagnostic assays for detecting cancer and therapeutic methods and compositions for treating cancer. The invention also provides methods for designing, identifying, and optimizing therapeutics for cancer. | 09-16-2010 |
| 20100196876 | Methods and Reagents for Genotyping HCV - The present invention is directed to methods and reagents for determining the genotype of a hepatitis C virus (HCV) species present in a test sample. The invention more particularly relates to mixtures of degenerate amplification and sequencing primers, and methods of using such primers, that are complementary to a plurality of HCV species, and are capable of generating nucleotide sequence information for a region of NS5B of HCV that is, for each species, indicative of the type and/or subtype, of the species present in the sample. | 08-05-2010 |
| 20100190972 | Heteropolynucleotide Duplexes With Purine-Purine Base Pairing - The present invention relates to stable anti-parallel heteropolynucleotide duplexes, comprising a plurality of complementary purine-purine nucleobase dyads, wherein the nucleobase is coupled to a pentose sugar backbone. The present invention further relates to methods of hybridizing two heteropolynucleotide molecules to form such purine-purine nucleobase dyads, as well as kits and solid supports comprising such purine-purine nucleobase dyads. | 07-29-2010 |
| 20100190169 | SINGLE NUCLEOTIDE POLYMORPHISMS PREDICTING CARDIOVASCULAR DISEASE - The present invention relates to an isolated polynucleotide encoding a Na | 07-29-2010 |
| 20100184110 | PREDICTIVE DIAGNOSTICS FOR KIDNEY DISEASE - The present invention relates to markers for kidney disease. | 07-22-2010 |
| 20100173339 | PLATELET ACTIVATION MARKERS AS INDICATORS FOR ANTI-PLATELET THERAPY - Methods for determining the appropriateness of anti-platelet therapy in a patient with a platelet-affected disease. The Mean Platelet Component value in a patient blood sample is determined corresponding to the patient's platelet activation status. A high platelet activation status indicates the appropriateness of anti-platelet therapy. | 07-08-2010 |
| 20100167261 | PLATELET STABILIZATION - Provided are methods for stabilizing mean platelet component and/or platelets in a sample comprising combining said sample with EDTA, a second anticoagulant, and one or more kinase inhibitors. Also provided are compositions for stabilizing a sample comprising platelets, and kits for storing a platelet sample. | 07-01-2010 |
| 20100150779 | Automated Analyzer - An automated analyzer for analyzing patient samples. The analyzer includes a plurality of cuvettes, which allow the samples to be mixed with various reagents. The analyzer includes one or more detectors, including a detector adapted to detect luminescence of the reaction mixture in the cuvettes. The analyzer allows for various diagnostic assays to be performed on a single system, and provides for high-sensitivity analysis at faster speeds. | 06-17-2010 |
| 20100150778 | Detection of Adulterated Samples - In some embodiments, the present invention pertains to a method for detecting an adulterant in a biological sample. A combination of a biological sample, an agent for detecting the adulterant and an ionic moiety capable of undergoing reduction by gaining electrons is provided in an assay medium. The combination is incubated under conditions sufficient for the ionic moiety to undergo reduction and for the agent for detecting the adulterant to interact with the adulterant. The reduction of the ionic moiety enhances the detection of the adulterant as a result of increasing the sensitivity of the agent for detecting the adulterant. The extent of interaction between the agent for detecting the adulterant and the adulterant is measured and is related to the presence or absence of the adulterant in the biological sample. | 06-17-2010 |
| 20100136541 | IDENTIFICATION AND VERIFICATION OF METHYLATION MARKER SEQUENCES - The present invention relates to methods for identifying among the genes that are down-regulated in cells or tissues having disease including cancer, the CpG sites within the CpG islands of said genes, wherein the identified CpG sites show great potential for diagnostic utility. In another aspect, the present invention also provides methods of using the selected CpG sites for purposes of diagnosis, prognosis, staging, assessing or monitoring the therapy of or recovery from a disease such as cancer. | 06-03-2010 |
| 20100112567 | RANDOM ACCESS SYSTEM AND METHOD FOR POLYMERASE CHAIN REACTION TESTING - A random access, high-throughput system and method for preparing a biological sample for polymerase chain reaction (PCR) testing are disclosed. The system includes a nucleic acid isolation/purification apparatus and a PCR apparatus. The nucleic acid isolation/purification apparatus magnetically captures nucleic acid (NA) solids from the biological sample and then suspends the NA in elution buffer solution. The PCR testing apparatus provides multiple cycles of the denaturing, annealing, and elongating thermal cycles. More particularly, the PCR testing apparatus includes a multi-vessel thermal cycler array that has a plurality of single-vessel thermal cyclers that is each individually-thermally-controllable so that adjacent single-vessel thermal cyclers can be heated or cooled to different temperatures corresponding to the different thermal cycles of the respective PCR testing process. | 05-06-2010 |
| 20100107784 | Actuated Septa and Systems and Methods Using the Same - A device, system, and method for passively sealing a vessel containing a fluid and for sampling the fluid without carry-over or cross-contamination between the fluid sampling device, the sealing septum, and the vessel contents. The device includes an actuated septum having a plurality of septum fingers, to passively seal the vessel, and an actuation device, to open the passive seal without carry-over or cross-contamination. Each of the plurality of septum fingers includes a corresponding rib portion. The actuation device can be an actuation ring having an annulus. The plurality of septum fingers and corresponding rib portions are disposed internal or substantially internal to the vessel, while the actuation device is disposed external to the vessel. | 05-06-2010 |
| 20100105041 | REAGENTS AND METHODS FOR DETECTING CYP2D6 POLYMORPHISMS - The present invention relates to oligonucleotide sequences for amplification primers and detection probes and their use in nucleic acid amplification methods for the specific detection of clinically relevant CYP2D6 polymorphisms, in particular CYP2D6 polymorphisms associated with adverse drug response. The oligonucleotide sequences are also provided assembled as kits that can be used to predict how an individual will respond to drugs or other xenobiotic compounds that are metabolized, at least in part, by CYP2D6. | 04-29-2010 |
| 20100099108 | Method for Detecting, Isolating, and Characterizing Cells from Body Samples by Transfection with Nucleic Acid Constructs - A method for detecting or isolating disease-associated cells or pluripotent stem cells from body samples is provided where cells of a body sample are transfected with nucleic acid constructs that include the following components: (a) a promoter element containing at least one DNA site for binding one or more transcription factors; and (b) a reporter gene that enables the diseased or stem cells to be detected. When the method is used for detecting disease-associated cells, the transcription factor initiates at least one signalling activity in the disease-associated cells that is not present in healthy cells. | 04-22-2010 |
| 20100099077 | STABLE ACRIDINIUM ESTERS WITH FAST LIGHT EMISSION - Chemiluminescent acridinium esters are provided which are fast light emitting and hydrolytically stable. The chemiluminescent acridinium esters are useful labels in assays for detecting or quantifying analytes. | 04-22-2010 |
| 20100093109 | PIEZO DISPENSING OF A DIAGNOSTIC LIQUID INTO MICROFLUIDIC DEVICES - Assays in which samples of biological fluids are dispensed into the inlet port of a microfluidic device are improved in the accuracy and repeatability by dispensing the biological sample and/or associated liquids in small droplets and at timed intervals to control the operation of the microfluidic device. | 04-15-2010 |
| 20100062459 | Tacrolimus Standard and Methods of Using Same - A composition and kit useful as a tacrolimus standard solution for immunoassays, and methods for making and using same. The composition and kits include a known amount of tacrolimus or a derivative thereof, and a non-specific protein capable of forming a complex with the tacrolimus or derivative thereof. The standard solution may be used to generate calibration curves for an immunoassay or to check the precision of an analytical instrument. | 03-11-2010 |
| 20100055798 | Degenerate Nucleobase Analogs - The present invention relates to novel degenerate nucleobase analogs and degenerate nucleobase oligomers derived therefrom, and methods of using such degenerate nucleobase oligomers. | 03-04-2010 |
| 20100047800 | Reagents and Methods for Detecting CYP2C9 Polymorphisms - The present invention relates to oligonucleotide sequences for amplification primers and detection probes and their use in nucleic acid amplification methods for the specific detection of clinically relevant CYP2C9 polymorphisms, in particular CYP2C9 polymorphisms associated with adverse drug response. The oligonucleotide sequences are also provided assembled as kits that can be used to predict how an individual will respond to drugs or other xenobiotic compounds that are metabolized, at least in part, by CYP2C9. | 02-25-2010 |
| 20100009412 | Novel Oligonucleotide Primers and Methods for DNA Replication - The present invention relates to methods and oligonucleotide primers for initiating polymerase-catalyzed DNA synthesis at a target region on a polynucleotide template, using an oligonucleotide primer comprising (i) a 5′ universal sequence or extension sequence; (ii) a 3′ target-specific primer sequence corresponding to a target region on the polynucleotide template; and (iii) an extension sequence linking the universal sequence or extension sequence with the target specific primer sequence. | 01-14-2010 |
| 20100009375 | Silica Magnetic Particles with a High Nucleic Acid Binding Capacity - Magnetic particles for nucleic acid isolation are coated with silica and separated from impurities and nanoparticulates using a multi-step fractionation process. In each cycle of the fractionation process, the particles are stirred, sedimented, and resuspended, resulting in a decline in pH of the suspended particles. Repeating the fractionation process until the resuspended particles have dropped to a target pH in the range of about 9 to 10.5, and their zeta potential is more negative than about −40 mV, results in a purified population of particles with a high and reproducible binding capacity for nucleic acids. The silica-treated magnetic beads produced by the method offer improved sensitivity and consistency for recovery of nucleic acids in a sample. | 01-14-2010 |
| 20090318627 | SOLID PHASE SYNTHESIS OF ACRIDINIUM DERIVATIVES - Acridinium-functionalized solid-phase supports and methods for making acridinium-functionalized solid-phase supports are disclosed. The acridinium-functionalized solid-phase supports comprise a solid phase support linked to a chemiluminescent substituted acridinium compound through a linker group covalently attached to the nitrogen atom of the acridinium nucleus and the solid phase support as exemplified in FIG. | 12-24-2009 |
| 20090318276 | Centrifuge Loading Process Within An Automated Laboratory System - A scheduling process for loading samples into two or more centrifuges in a loading scheme that reduces the time required for high priority sample to be centrifuged. One centrifuge is initially loaded to about one-half of capacity and samples processed while the remaining centrifuge is loaded to full capacity before being operated. This creates a time-shift in the operational status of the two centrifuges so that a high-priority sample may advantageously be shuttled to whichever of the two centrifuges will be first-fully loaded and thus next-operated. | 12-24-2009 |
| 20090316140 | METHOD AND APPARATUS FOR USING INFRARED READINGS TO DETECT MISIDENTIFICATION OF A DIAGNOSTIC TEST STRIP IN A REFLECTANCE SPECTROMETER - A method and apparatus for using an infrared reading to detect the misidentification of a diagnostic test strip disposed on a feed table comprising the steps of determining if the test strip possesses specified reagents, reading the infrared reflectances from the reagent positions, determining if the reflectances are within an acceptable predetermined range and aborting the test if the infrared reflectances are not within the acceptable predetermined range. | 12-24-2009 |
| 20090294677 | METHOD FOR SIGNAL INTENSITY CORRECTION IN WAVEGUIDE SENSORS - Methods are provided for enhancing the detection of analytes with waveguides by accounting for cumulative light absorptions attributable to the presence of one or more analytes in a sample as well as the waveguide material. | 12-03-2009 |
| 20090280493 | Methods and Compositions for the Prediction of Response to Trastuzumab Containing Chemotherapy Regimen in Malignant Neoplasia - The invention relates to methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of neoplastic disease. Neoplastic disease is often caused by chromosomal rearrangements which lead to over- or underexpression of the rearranged genes. The invention discloses genes which are overexpressed in neoplastic tissue and are useful as diagnostic markers and targets for treatment. Methods are disclosed for predicting, diagnosing and prognosing as well as preventing and treating neoplastic disease. | 11-12-2009 |
| 20090266149 | Differentiating Between Abnormal Sample Viscosities and Pipette Clogging During Aspiration - A method for differentiating between a liquid sample having clogs therein and a liquid sample having an abnormally elevated viscosity during a liquid aspiration process by relating the ratio between the maximum negative pressure during aspiration and an equilibrium pressure prior to dispensation to viscosity. | 10-29-2009 |
| 20090239223 | Prediction of Breast Cancer Response to Taxane-Based Chemotherapy - The invention relates to methods and kits for the prediction of a likely outcome of chemotherapy in a cancer patient. More specifically, the invention relates to the prediction of tumour response to chemotherapy based on measurements of expression levels of a small set of marker genes. The set of marker genes is useful for the identification of breast cancer subtypes responsive to taxane based chemotherapy, such as e.g. a taxane-anthracycline-cyclophosphamide-based (e.g. Taxotere (docetaxel)-Adriamycin (doxorubicin)-cyclophosphamide, i.e. (TAC)-based) chemotherapy. | 09-24-2009 |
| 20090208987 | Method and Composition for Stabilizing Liquid Reagents - The invention relates to methods and compositions for removing a dissociated species from a fluid medium solution during and after it has detached from a solid-phase immersed in said medium, thereby allowing the concentration of free species to remain close to zero, and for improving the signal to noise ratio in assays. This is achieved by employing a substrate, such as a scavenging solid-phase, having an attached binding partner or partners (“scavenger”) for the specifically binding species and which is present during storage. This substrate may also contain regions for binding signal generating components attached to the solid-phase. This substrate binds any free species bleeding off the solid phase, increasing the reliability and sensitivity of assays. A subset of the substrates in the invention additionally forms cross-linked networks of solid-phase particles that further increase the sensitivity of assays. | 08-20-2009 |
| 20090150315 | Neoplastic Disease-Related Methods, Kits, Systems and Databases - In one embodiment, the invention provides methods for predicting a clinical outcome of a patient's neoplastic disease comprising: (a) determining a predictor value algorithmically using patient sample values for (1) at least one tumor marker or at least one immune marker, and (2) at least one marker that is (i) an extracellular matrix (ECM) marker (ii) a marker that is indicative of extracellular matrix synthesis (fibrogenesis), or (iii) a marker that is indicative of extracellular matrix degradation (fibrolysis); and (b) predicting the clinical outcome of the neoplastic disease by evaluating the predictor value. | 06-11-2009 |
| 20090143275 | ADIPONECTIN RECEPTOR FRAGMENTS AND METHODS OF USE - Methods are disclosed of treating diabetes, abnormal adipocyte activity, and insulin resistance using C-terminal fragments of adiponectin receptor R1. Methods of causing the secretion of insulin in healthy and diabetic patients using C-terminal fragments of adiponectin receptor R1 are also disclosed. In addition, methods are disclosed of increasing the insulin levels in healthy patients using C-terminal fragments of adiponectin receptor R1. In addition, methods of treating abnormal adipocyte activity, treating metabolic syndrome, causing insulin secretion, increasing insulin levels, inhibiting insulin degradation enzyme, treating Alzheimer's disease, treating cardiovascular disease associated with adiponectin levels, inhibiting ADAM-17 enzyme, treating a condition associated with TNF-alpha, and treating a condition associated with HER2-neu are disclosed. Compositions, dosage forms, and kits are also disclosed. | 06-04-2009 |
| 20090138204 | Single nucleotide polymorphisms sensitively predicting adverse drug reactions (ADR) and drug efficacy - Provided are diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy or whether the human subject is a high or low responder or a good a or bad metabolizer of statins. The diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. Also provided are polymorphic sequences and other genes and isolated polynucleotides encoding a phenotype associated (PA) gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat cardiovascular disease or influence drug response. | 05-28-2009 |
| 20090087865 | Monoclonal Antibodies to Tacrolimus and Immunoassays Methods for Tacrolimus | 04-02-2009 |
| 20090075273 | Planar Waveguide Detection Chips and Chambers for Performing Multiple PCR Assays - Provided are planar waveguide (“PWG”) detection chips that are used to perform multiplex PCR and kinetic PCR assays with a single fluorescent dye. The PWG detection chips are housed in PWG detection chambers that house at least one PWG chip. The PWG detection chambers may be in a single chamber or a dual chamber configuration. Also provided are methods for analyzing amplification products using the PWG detection chambers of the present invention. | 03-19-2009 |
| 20090041627 | PACKAGING OF MICROFLUIDIC DEVICES - A microfluidic device containing liquid reagents having an extended shelf life contains the liquid reagents in micro-reservoirs that limit the escape of moisture to less than 10% over the shelf life of the device. The micro-reservoir preferably is made of polypropylene and covered with a metallized plastic film. | 02-12-2009 |
| 20090034902 | Method for Increasing Signal Intensity in An Optical Waveguide Sensor - A sensor platform for use in sample analysis comprises a substrate ( | 02-05-2009 |
| 20090029435 | Deactivation of Linking Moieties in Antibody-Enzyme Conjugates - In some embodiments, the present invention pertains to a method for conjugating a first compound to a second compound wherein the conjugation involves an electrophilic moiety. The method comprises reacting the first compound with the second compound to form a conjugate. The improvement in embodiments of the present invention comprises adding a nucleophilic reagent to the conjugate wherein the nucleophilic reagent forms a neutral product upon reaction with unreacted electrophilic moieties of the conjugate. In some embodiments, the nucleophilic reagent is substantially non-reactive with disulfide bonds in the event that the conjugate comprises disulfide bonds. The conjugate formed is doubly deactivated because the other moiety for linking to the electrophilic moiety is also deactivated. | 01-29-2009 |
| 20090023597 | Single Nucleotide Polymorphism Detection from Unamplified Genomic DNA - The present invention provides methods, compositions and systems for the specific and selective detection of multiple single nucleotide polymorphisms (SNPs) from genomic DNA. Importantly, the inventive systems and methods eliminate the need for costly, time- and labor-intensive gene amplification that is generally carried out prior to SNP detection. Also provided are kits useful to perform the inventive methods. | 01-22-2009 |
| 20090023181 | Method and Device for Detection of Erythromycin-Induced Clindamycin Resistance - A device and method are provided for determination of erythromycin-induced clindamycin resistance. The device is preferably a test panel containing one or more wells each having a known concentration(s) of erythromycin and known concentration(s) of clindamycin. After inoculation of the wells with a sample and incubation, the wells are analyzed for growth and to determine whether sample contains a microorganism that expresses erythromycin-induced clindamycin resistance. | 01-22-2009 |
| 20090004059 | METHOD AND APPARATUS FOR PRECISE TRANSFER AND MANIPULATION OF FLUIDS BY CENTRIFUGAL AND OR CAPILLARY FORCES - A micro-liter liquid sample, particularly a biological sample, is analyzed in a device employing centrifugal and capillary forces. The sample is moved through one or more sample wells arrayed within a small flat chip via interconnecting capillary passageways. The passageways may be either hydrophobic or hydrophilic and may include hydrophobic or hydrophilic capillary stops. | 01-01-2009 |
| 20080312420 | Monoclonal Antibodies for Detection of Urinary Trypsin Inhibitors - Certain monoclonal antibodies are able to detect urinary trypsin inhibitors (UTIs) that are characteristic of disease in humans. In particular, the UTIs include AMBK, Bikunin, Uristatin, Uristatin-1, Uristatin-2, as defined herein, also including the fragments and aggregates thereof. | 12-18-2008 |
| 20080306696 | Methods for Resolving Convoluted Peaks in a Chromatogram - The present invention relates to methods for resolving convoluted peaks in a chromatogram into one or more constituent peaks using peak resolution values. The peaks methods of the invention determine empirical peak resolution values of “well-defined” or “isolated” peaks in the data, then extrapolate these empirical resolution values to peaks in neighboring regions to predict the number of constituent peaks at a given peak position. Predicted peak resolution values are compared to observed peak resolution values of low-resolution or convoluted peaks to determine the number of constituent peaks in the convoluted peaks. These methods enable extension of the region of data that can used for identifying nucleotide sequences, and increase base-calling accuracy in the low-resolution region (end region) of data. | 12-11-2008 |
| 20080306694 | Methods for Detecting Peaks in a Nucleic Acid Data Trace - The present invention relates to methods and apparatus for detecting peaks in a sample nucleic acid data trace derived from a sample polynucleotide by (a) receiving a sequence signature of a reference polynucleotide, wherein the sequence signature comprises a profile of peak height at one or more peak position of a nucleic acid sequence data trace of one or more of reference polynucleotides; (b) receiving a sample nucleic acid sequence data trace of a sample polynucleotide corresponding to the reference polynucleotide, wherein the sample nucleic acid sequence data trace comprises a value of peak height at one or more peak position corresponding to the peak positions of the sequence signature; and (c) detecting peaks in the sample nucleic acid data trace having a peak height that correlates with the profile of peak height of the sequence signature at a corresponding peak position. | 12-11-2008 |
| 20080261324 | System, Device and Method for Reducing Luminescence Output Shifts - Devices, systems, and methods for conducting chemiluminescent immunoassay testing and, more particularly, to initiating and monitoring a chemiluminescent reaction in a plurality of such assays, of different types, on a single immunoassay instrument, in a single procedure, using a plurality of labels and a triggering reagent combination are disclosed. Moreover, by including a base reagent injector assembly having an “e-channel” to provide a swirling turbulence to the base reagent immediately before it is introduced into the well of a cuvette containing a sample and an acid reagent. The added turbulence addresses the phenomenon referred to as “RLU shift,” in which the luminescence output can increase or decrease between assays. | 10-23-2008 |
| 20080261227 | Kinetic Pcr Assay for Quantification of Gene Amplification on Chromosome 17 - Provided is a kinetic PCR (“kPCR”) assay for determining gene copy number of a target gene located on chromosome 17. The kPCR assay uses the MMP-28 gene located at the 17q11.2-17q12 loci as a control and thus, is capable of detecting gene copy number of any gene on chromosome 17 in both singleplex and multiplex format without the need for a standard curve. The kPCR assay is useful for determining the gene copy number of the HER2/neu gene located at loci 17q12-17q21.32, which is a requirement for determining if a breast cancer patient is a candidate for anti-HER2/neu gene therapy. | 10-23-2008 |
| 20080233582 | SINGLE NUCLEOTIDE POLYMORPHISMS ASSOCIATED WITH SUSCEPTIBILITY TO CARDIOVASCULAR DISEASE - The present invention provides SNPs, polymorphic variants, and haplotypes associated with cardiovascular disease. The invention also provides methods for detecting the SNPs, polymorphic variants, and haplotypes. The invention also provides methods for determining an individual's genotype with respect to one or more polymorphisms and/or haplotypes associated with cardiovascular disease. The invention further provides methods of determining whether an individual has or is susceptible to development or occurrence of a cardiovascular disease or event. The methods are useful for providing diagnostic and/or prognostic information, selecting therapeutic regimens, etc. The invention further provides reagents and kits for practicing the methods. | 09-25-2008 |
